Global Transgenic Animals Market 2026 – 2035

It is projected that the market size of the global transgenic animals market will be USD 3.42 billion in 2025, and that the market size will increase to USD 3.76 billion in 2026 and to approximately USD 7.89 billion in 2035, at an annual CAGR of 10.1% between 2025 and 2035.

The market will expand due to the rising demand of personalized medicine and targeted therapies, increased investments in pharmaceutical research and development, the rise in prevalence of chronic and genetic diseases, technological advancements in gene editing tools, especially CRISPR/Cas9, and increased applications in regenerative medicine and xenotransplantation.

Market Highlight

• North America was the leader in the market of transgenic animals with a market share of 45% in the year 2025.

• Asia Pacific will increase by 12.8% in the time frame between the years 2026 and 2035.

• By type, the mice segment had assumed more than 52% of the market share in 2025.

• By application, the research & development segment will have the greatest CAGR of 11.2% between 2026 and 2035.

• The CRISPR/Cas9 gene editing segment will have the highest CAGR of 13.5% in the period of the forecast, 2026-35.

• Pharmaceutical and biotechnology companies captured 49% of the market share in 2025 by the end user.

• The market of transgenic mice models alone in 2024 is expected to reflect some 58% of the aggregate transgenic animal market value.

Significant Growth Factors

• Surging Demand for Precision Medicine and Targeted Drug Development

The world has gone global and switched towards the use of precision medicine and personalized therapeutics, and this has necessitated an unparalleled pressure on the use of transgenic animal models that can precisely recapitulate human diseases, both at the molecular and genetic levels. The National Institutes of Health says that since 2015, more than 1.5 billion US dollars have been allocated to precision medicine projects, and pharmaceutical firms have invested another 12.3 billion US dollars in the development of targeted therapies each year. Transgenic animals allow investigators to examine a particular gene mutation, perform therapeutic intervention research in controlled settings and forecast human responses to new treatments with 73% greater accuracy than with conventional animal models.

In 2024, the market value of precision medicine in the world was 68.4 billion, and it is expected to grow to above 145 billion in 2032; it is the direct driver of the high demand of complex transgenic models. Mice genetically modified to carry genes that cause diseases in humans have become a critical tool in gaining insights into cancer, Alzheimer's disease, cardiovascular diseases and rare hereditary diseases. Colonies of transgenic mice in research institutions worldwide have over 25,000 different transgenic mouse strains with the Jackson Laboratory alone distributing more than 3 million mice per year to 2,400 institutions in 65 countries. The dependence of the pharmaceutical industry on the usage of transgenic models is supported by the fact that 94% of the drugs that are approved by the FDA are pre-clinically tested using the genetically modified animals and oncology drugs need the use of 5-8 different transgenic models in the development stages incurring a cost of 15-25 million dollars per successful drug candidate.

• Technological Revolution in Gene Editing Enabling Rapid Model Generation

Technological Revolution in Gene Editing Enabling Rapid Model Generation: With the introduction of CRISPR/Cas9 and other state-of-the-art technologies in gene editing, the long generation times (12-18 months) and generation costs (60-75% higher than the traditional pronuclear microinjection) have been dramatically reduced, making it possible to generate models with great efficiency generating them in under three weeks and generating them at significantly reduced costs. Nobel Prize Winner CRISPR technology allows accurate targeting of the genome with 95% accuracy in mouse embryos and 78% accuracy in full mammals such as pigs and cattle. Gene editing technology market currently stands at $5.8 billion in 2024 and the applications of CRISPR are increasing at a rate of 18.2 per year. Since 2015, more than 15,000 new CRISPR-modified animal models have been created by academic institutions and commercial suppliers, and these add to the repertoire of biomedical research.

Next-generation CRISPR derivatives created in 2019-2022 allow even more accurate genetic editing without breaking strands of DNA Base editing and prime editing allow a higher precision of genetic editing, with a single nucleotide change at an 89% accuracy rate. This technology has made possible transgenic pigs that have been humanized in organs to be used in xenotransplants, eGenesis and United Therapeutics have reported success in transplanting kidneys of a genetically modified pig into human patients in 2024. The price is reduced significantly: it cost $45,000-65,000 to make a simple transgenic mouse line in traditional systems and now costs $12,000-18,000 in CRISPR, so smaller research facilities can now afford to make transgenic lines.

What are the Major Advances Changing the Transgenic Animals Market Today?

• CRISPR/Cas9 and Advanced Gene Editing Platforms

CRISPR/Cas9 technology has relegated transgenic animal production to an entirely new level of precision, speed, and versatility in genome editing. The mechanism involves employing guide RNA molecules to target Cas9 nuclease enzymes to desired DNA sequences to accomplish a cut that targets desired gene knockout, insertion, or replacement with 92-98% accuracy in the majority of mammalian species. The capabilities of CRISPR have been extended to include base editors that can chemically convert single bases of DNA without nicking the double helix, prime editors that can be used to make targeted insertions, deletions, and all 12 base-to-base conversions, and epigenome editors that can be used to regulate gene expression but not modify the DNA sequence.

The technology allows multiplexed editing in which the researchers can edit 5-10 different genes in one generation, which used to take years of breeding to achieve. Commercial services such as Charles River Laboratories, Taconic Biosciences and Cyagen Biosciences provide CRISPR based custom model generation services that include a 12-16 week mouse turnaround time and an 8-12 month turnaround time on larger species. Statistical analysis demonstrates that CRISPR has minimized failed attempts in the generation of transgenes that were 45-60% failure rates with previous means of research to 8-15% with refined CRISPR instructions greatly enhancing the efficiency of research.

• Humanized Transgenic Models for Drug Safety and Efficacy Testing

The humanized transgenic animals that have functional human genes, cells, tissues or organs are the state of the art models that will help us in closing the gap of translational research between the preclinical research and human clinical studies. These models use the human immune system, liver enzymes, the metabolism of drugs or whole physiological systems that allow better prediction of drug effects and side effects and effectiveness in human populations. Immunotherapies, vaccines and treatment of infectious diseases can be tested using humanized mouse models which have reconstituted human immune systems and have a predictive accuracy of 84% of human results compared to 43% with standard mouse models. There is a growing trend of using humanized models in regulatory submissions in the pharmaceutical industry, where the FDA is promoting their use in toxicology and efficacy studies. Firms such as

The Jackson Laboratory and Champions Oncology have been able to come up with standardized humanized mouse models that use human tumor xenografts and patient-derived immune cells that are used in personal oncology research. A market of humanized models worth more than 245 million in 2024 is increasing at a rate of 14.6% per year as pharmaceutical firms target ways to cut late-stage clinical trial failure, which is estimated to cost them in the form of 800 million to 2 billion USD per failed drug candidate.

• Large Animal Transgenic Models for Translational Research

Translational research Large animal transgenic models, such as transgenic pigs, cattle, sheep, and non-human primates, are being used increasingly because physiological similarity to humans gives them benefits over rodent models, especially in cardiovascular research, organ transplantation, regenerative medicine, and modeling complex diseases. The similarity of pigs to humans is 84%, as do the size of their organs and their cardiovascular structures and mechanisms, as well as their disease development in such conditions as atherosclerosis and diabetes, as well as neurodegenerative diseases.

The CRISPR technology has improved the development of transgenic pigs, with up to 69 genetic mutations being achieved in pigs to avoid organ rejection in xenotransplantation models. As of January 2024, clinical trials of xenotransplantation were shown to be possible when surgeons at the University of Maryland were able to transplant a genetically modified pig heart into a human patient who survived 60 days. The worldwide organ shortage problem, where 103,000 Americans are waiting to receive organs through transplantation and 17 people are dying each day before receiving organs, is pushing investors to invest in transgenic pig organ development. Other firms such as the Revivicor subsidiary of United Therapeutics and eGenesis have raised more than 450 million dollars in funds on transgenic pig programs based on kidney, heart and liver xenotransplantation.

• Biopharmaceutical Production in Transgenic Animals

Examples of biopharmaceutical production through transgenic animals include Transgenic animals producing human therapeutic proteins in milk, blood or even eggs: A rising biomanufacturing platform, these animals have demonstrated benefits in protein folding, post-translational modifications, and scalability of production in comparison to bacterial systems and cell culture systems. Transgenic goats, sheep and cattle express complex human proteins in milk at levels up to 10-40 grams per liter, and a single transgenic dairy cow can be capable of producing 200-800 kilograms of therapeutic protein per year.

In 2009, ATryn, a recombinant human antithrombin made in transgenic goat milk was the first transgenic animal-made drug to be approved by the FDA, followed in 2014 by Ruconest produced in transgenic rabbit milk. The technology has been especially useful in the generation of monoclonal antibodies, blood clotting factors, and complex glycoproteins that do not glycosylate using the mammalian pattern in bacterial or yeast systems. This is shown by industry analysis which provides that transgenic animal bioproduction can make manufacturing 40-60% less than with traditional cell culture of some proteins and production units take 70% less capital investment than comparable bioreactor plants.

Category Wise Insights

By Type

Why Mice Lead the Transgenic Animals Market?

The mice market is the largest with a predicted market share of 52% in 2025 because of biological benefits such as short generation times of 8-12 weeks leading to quick breeding, small size of the mouse leading to low housing and maintenance costs of $1-3 per mouse per day, well-characterized genetics with full genome sequencing, and high availability of reagents. Mice are outstanding models when it comes to studying human diseases because their genome is 85% similar to human beings.

The cost-effectiveness is high such that transgenic mouse generation incurs 12000-25000 dollars per line of transgenic mice, as opposed to rats that incur 85000-150000 dollars, or rabbits that incur 200000-500000 dollars. International research centers keep in excess of 25 million lab mice and transgenic and gene-edited mice constitute about 65% of this number. In the repository of the Jackson Laboratory are 11,500 strains of which 8,700 are genetically modified, and the International Mouse Phenotyping Consortium has characterized more than 8,500 knockout mouse strains. The mouse research has technological infrastructure that is incomparable, and known standardized protocols, automated phenotyping platforms and long historical data facilitate an effective experimental design and interpretation.

By Application

Why Research & Development Dominates Applications?

The highest market share of about 47% in 2025 is held by research and development applications due to the primary biomedical research needs such as the requirement of disease models, pharmaceutical drug discovery programs, safety and efficacy testing, and academic studies of gene function and biological mechanisms. In 2024, the National Institutes of Health paid around 47.6 billion to biomedical research, and an approximate 68% of this funding was used on projects that made use of transgenic animal models at one point. By 2024, pharmaceutical R&D expenditure throughout the world had increased to 237 billion dollars with preclinical research taking up 25-30% of budgets and transgenic animals forming the heart of drug candidate tests and validation.

Every year more than 45,000 peer-reviewed papers using transgenic animal models are published in academic institutions including neuroscience, immunology, developmental biology, and many others. The research application sector boasts of ongoing improvement in model generation with new disease-relevant strains being engineered continuously to answer new scientific inquiries and therapeutic goals.

By Technology

Why CRISPR/Cas9 Shows Fastest Growth?

CRISPR/Cas9 gene editing technology has the highest CAGR of 13.5% in 2026-2035 because it has better precision allowing modifications to the base pair level, shorter generation times of 3-6 months compared to 12-18 months of traditional technology, cost savings of 60-75% compared to pronuclear microinjection, and the ability to perform knockout, knock-in, and conditional modification. Since its commercial release in 2013-2014, 78% of transgenic animal facilities around the globe have already adopted the technology. Trends of publications indicate that the number of research papers on CRISPR has risen from 420 in 2013 to more than 18,500 in 2024 and is growing intensively in biomedical sciences.

Current efficiency is strong: CRISPR shows a germline success rate in 85-95% of founder animals, in contrast to 15-30% offered by conventional microinjection, further necessitating significantly less breeding of animals and decreasing colony maintenance costs by huge margins. Service providers in the commercial sphere testify to the fact that CRISPR projects today are 72% of new orders of transgenic animals, and in 2015 it was 18%, which shows that the market turns.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America transgenic animals market size is estimated at USD 1.54 billion in 2025 and is projected to reach approximately USD 3.28 billion by 2035, with a 9.8% CAGR from 2026 to 2035.

Why did North America Dominate the Market in 2025?

The United States has the largest market share of 45% in 2025 because it has the greatest concentration of pharmaceutical and biotechnology companies with more than 3,200 firms performing drug development, extensive research infrastructure with more than 1,850 universities having biomedical research programs, substantial NIH funding of above 47 billion in a year, major suppliers of transgenic models, and well-developed regulation systems that enable the advancement of genetic research. The US conducts 62% of the total preclinical research of the pharmaceutical industry in the world, generating enormous demand for transgenic models. Colleges such as Harvard, MIT, Stanford and Johns Hopkins have state of the art transgenic core facilities that produce thousands of custom models a year.

The Jackson Laboratory in Maine has the largest collection in the world containing 11,500 mouse strains and supplies 3.1 million mice per year across the world. In North America in 2024, pharmaceutical research and development expenditure was up again to $118 billion, with biotechnology firms becoming increasingly dependent on transgenic systems to validate their targets and test their therapeutic proteins.

What is the Size of the U.S. Market?

It is estimated that the market size of transgenic animals will reach USD 1.38 billion in the U.S. in 2025 and it is expected to increase at a rate of 9.7% between 2026 and 2035.

Why is Asia Pacific Experiencing Rapid Growth?

The fastest growth is in Asia Pacific at 12.8% CAGR between 2026-2035, with the growing investments in pharmaceutical research and development in China, growing biotechnology industries in China, India, and South Korea, government efforts to encourage and support life sciences research, and growing academic research facilities, as well as the inexpensive production capacity of transgenic models. China has become a powerhouse in transgenic animal production with plants in Shanghai, Beijing and Guangzhou providing services that are 40-50% cheaper than Western based services and with international quality standards. The Made in China 2025 initiative of the Chinese government has placed biotechnology as one of its strategic priorities with $145 billion to be spent on biotech development by the year 2030. The biotechnology industry increased to 80 billion dollars in India in 2024, and there is a rising trend of transgenic models being used by pharmaceutical research carried out by Indian firms such as Sun Pharma, Dr. Reddy, and Biocon.

Why is Europe Focusing on Alternative Methods?

Europe already has a high market share and focuses on the 3Rs principle (Replacement, Reduction, and Refinement) due to regulations that justify animal use and the search for alternative possibilities. The European market would be worth 945 million in 2025 and the growth would be mitigated by the high standards of animal welfare in the form of the strict Directive 2010/63/EU that has to be subjected to and prove that no viable alternatives exist. Although there are restrictions by the regulatory bodies, European pharmaceutical firms such as Roche, Novartis, AstraZeneca, and Sanofi have large transgenic model programs. More than 7,500 knockout mouse lines are maintained in the European Mouse Mutant Archive with 12,500 papers being published annually by European institutes that use transgenic models. Large animal transgenic studies are notably strong in the region with transgenic pig and cattle research centers in Germany, France, and the Netherlands in the lead in developing transgenic pigs and cows into agricultural and biomedical products.

Top Players in the Market and Their Offerings

• The Jackson Laboratory

• Charles River Laboratories

• Taconic Biosciences

• genOway S.A.

• Horizon Discovery Group

• Cyagen Biosciences

• PolyGene Transgenics

• Trans Genic Inc.

• Ingenious Targeting Laboratory

• Ozgene Pty Ltd

• Applied StemCell

• Others

Key Developments

• In March 2025: Charles River Laboratories purchased a transgenic pig model in Iowa, which cost it 145,000,000 dollars, increasing its large-animal models in xenotransplantation and cardiovascular disease research.

• In April 2025: Cyagen Biosciences introduced an AI-based design tool that optimizes the selection of CRISPR guide RNA, eliminating off-target effects by 73 percent and increasing the editing efficiency to 97 percent of mouse embryos.

These strategic activities have allowed companies to strengthen market positions, expand product offerings, enhance technological capabilities, and capitalize on growth opportunities within the expanding market.

The Transgenic Animals Market is segmented as follows:

By Type

• Mice

• Rats

• Rabbits

• Pigs

• Cattle

• Others

By Application

• Research & Development

• Biopharmaceutical Production

• Disease Modeling

• Xenotransplantation

• Others

By Technology

• Microinjection

• Gene Editing (CRISPR/Cas9)

• Retroviral Vector

• Others

By End User

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organizations

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America